Wedbush Maintains Outperform Rating on Tango Therapeutics Amid Pipeline Advancements

Wedbush Securities has maintained its Outperform rating on Tango Therapeutics (TNGX), reaffirming its positive outlook on the clinical-stage biopharmaceutical company. The firm highlighted the company’s advancing pipeline, particularly in solid tumor immunotherapies, as a key driver of sustained investor interest. Tango’s lead asset, TNGX-011, is currently in Phase 1b trials for advanced solid tumors, with data expected by mid-2026. The reiteration of the Outperform rating comes amid a broader trend of increased analyst attention on precision oncology platforms. Tango Therapeutics has raised approximately $180 million in equity financing since 2021, funding its discovery and development programs. The company’s proprietary SABER platform, designed to enhance immune cell targeting, underpins its pipeline of novel T-cell therapies. Market analysts note that TNGX-011’s potential to modulate tumor microenvironments could differentiate it in a competitive landscape. While the stock has experienced a 12% decline over the past 90 days due to broader biotech sector volatility, Wedbush’s continued endorsement suggests underlying confidence in Tango’s long-term value. The firm’s model-based valuation implies a target price of $28.50 per share, representing a 37% upside from current levels as of March 10, 2026. The reaffirmation may influence portfolio managers focused on mid-cap biotech stocks with clinical-stage assets. Investors and institutional traders monitoring TNGX are likely to reassess positioning in light of the maintained rating, particularly ahead of upcoming trial readouts and potential partnerships.